Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib in EGFR-mutant NSCLC with brain metastases
NCT02655536Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Aug 2017
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in non-small cell lung cancer (NSCLC) and brain neoplasms, sponsored by National Taiwan University Hospital. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)brain neoplasms
Beyond the preview
Go deeper on NCT02655536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02655536.